The stock of Aurora Cannabis Inc. (NYSE:ACB) is a huge mover today! The stock increased 12.94% or $1.03 during the last trading session, reaching $8.99. About 111.17 million shares traded or 378.38% up from the average. Aurora Cannabis Inc. (NYSE:ACB) has declined 10.79% since March 13, 2018 and is downtrending. It has underperformed by 15.16% the S&P500.
The move comes after 7 months positive chart setup for the $9.27 billion company. It was reported on Mar, 13 by Barchart.com. We have $9.35 PT which if reached, will make NYSE:ACB worth $370.72M more.
Analysts await Aurora Cannabis Inc. (NYSE:ACB) to report earnings on May, 14. They expect $-0.05 EPS, down 25.00 % or $0.01 from last year’s $-0.04 per share. After $-0.04 actual EPS reported by Aurora Cannabis Inc. for the previous quarter, Wall Street now forecasts 25.00 % negative EPS growth.
More notable recent Aurora Cannabis Inc. (NYSE:ACB) news were published by: Fool.com which released: “Aurora Cannabis Just Hit a Dubious Milestone – Motley Fool” on March 11, 2019, also Seekingalpha.com with their article: “Cronos leading pot stock rally – Seeking Alpha” published on February 04, 2019, Benzinga.com published: “Aurora Cannabis (NYSE:ACB) Appoints Nelson Peltz As Strategic Advisor: ‘Solid Execution, Strongly Differentiated From Its Peers’ – Benzinga” on March 13, 2019. More interesting news about Aurora Cannabis Inc. (NYSE:ACB) were released by: Fool.com and their article: “Tilray Leapfrogs Aurora Cannabis and Canopy Growth in the U.S. Hemp Market – The Motley Fool” published on February 20, 2019 as well as Seekingalpha.com‘s news article titled: “Why There Are At Least 2 Monster Years Ahead For Aurora Cannabis – Seeking Alpha” with publication date: February 01, 2019.
Aurora Cannabis Inc. produces and distributes medical cannabis products. The company has market cap of $9.27 billion. It is vertically integrated and horizontally diversified across various divisions of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. It has a 41.62 P/E ratio. The company’s products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.